SlideShare a Scribd company logo
Fever
National Pediatric Nighttime Curriculum
Written by Debbie Sakai, M.D.
Institution: Lucile Packard Children’s Hospital
Case 1
 4-month-old well-appearing girl admitted
for croup and respiratory distress.
Develops fever to 39.1.
What additional evaluation would you do at
this point?
Case 2
 12-year old boy with AML, in induction,
admitted for febrile neutropenia. He
had just received his first dose of
ceftazidime and vancomycin when he
developed another fever to 38.5, chills,
and new dizziness shortly after
receiving the antibiotics.
What would be the next steps in this
patient’s management?
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Which patients are high-risk for
sepsis?
 Neonates
 Transplant recipients
Bone marrow
Solid organ
 Oncology patients
Undergoing therapy, mucositis, central line
Most chemotherapy: nadir ~ 10 days after rx
 Asplenic patients, including sickle cell
Definition of fever
 38.0
 Neonates (< 12 months)
 Any immunocompromised patient
 Including transplant patients, patients with
immunodeficiencies, oncology patients (sustained ≥38 x 1
hour)
 38.5
 All other patients
 These are general guidelines, individual
patients/services may have different parameters
What etiologies cause fever?
 Infectious
 Inflammatory
 Oncologic
 Other: CNS dysfunction, drug fever
 Life-threatening conditions
Infectious
 Systemic
 Bacteremia, sepsis, meningitis, endocarditis
 Respiratory
 URI, sinusitis, otitis media, pharyngitis, pneumonia,
bronchiolitis
 Abdominal
 Urinary tract infection, abscess (liver, kidney, pelvis)
 Bone/joint infection
 Hardware infection
 Central line, VP shunt, G-tube
Inflammatory
 Kawasaki disease
 Juvenile inflammatory arthritis
 Lupus
 Inflammatory bowel disease
 Henoch-Schonlein purpura
Others
 CNS dysfunction
 Drug fever
Life-threatening conditions
 Sepsis, febrile neutropenia
 Vital sign instability, poor-perfusion, may have altered mental
status, disseminated intravascular coagulation
 Hemophagocytic lymphohistiocytosis
 Splenomegaly, bicytopenia, elevated ferritin, elevated
triglycerides, low fibrinogen, hemophagocytosis, low/absent NK
cell function, elevated soluble IL2 receptor
 Malignant hyperthermia
 Following administration of inhaled anesthetics or depolarizing
neuromuscular blockers (succinylcholine), at-risk patients
include those with myopathy
 Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Assessment
 Vital signs
 Repeat physical exam
 Overall appearance (sick, toxic)
 Central/peripheral lines
 Incisions/wounds
 VP shunt/tracheostomy/gastrostomy tube
 Oral mucosa/perineal area for neutropenic patients
 Perfusion
 Call for help if concerning vital signs/exam
 Fellow or attending
 Rapid response team (RRT)/PICU
Laboratory evaluation
 What would you do if the patient has
hardware (VP shunt, tracheostomy,
gastrostomy tube) or central line?
CBC with differential
Blood culture
CSF (tap VP shunt)
Laboratory evaluation
 What would you do if the patient has a
high risk for sepsis?
Immunocompromised
Transplant recipient
Oncology patient
CBC with differential
Blood culture
Urinalysis and urine culture
Laboratory evaluation
 What would you do for an infant ≤ 2
months of age?
CBC with differential
Blood culture
Catheterized urinalysis and urine culture
Lumbar puncture
Laboratory evaluation
 Who needs a urinalysis and urine culture?
Circumcised males < 6 months
Uncircumcised males < 1 year
Females < 2 years
Immunocompromised patients
Patients with history of UTI/pyelonephritis
Laboratory evaluation
 Who needs a lumbar puncture?
 Neonates ≤ 2 months
 Ill-appearing
 Altered mental status
 What tests do you send?
 Gram stain and culture
 Cell count and differential
 Protein and glucose
 Extra tube for additional studies
 Enteroviral PCR, HSV PCR, CA encephalitis project
Laboratory evaluation
 Consider CRP, ESR
 Consider PT/PTT, fibrinogen
 Consider chest x-ray
 Consider nasopharyngeal DFA
 For immunosuppressed patients consider:
Viral PCR studies (ie CMV, EBV, HHV6)
Additional imaging (ie ultrasound, CT scan)
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Treatment for non-high risk patients
 May not need empiric antibiotics
 Consider the following issues:
Is patient clinically stable?
Are the screening laboratory studies
suggestive of infection?
Treatment for patients with central
lines
 Ceftriaxone
 Vancomycin
Treatment for neonates ≤ 2 months
 If < 28 days old
Ampicillin AND cefotaxime OR
Ampicillin AND gentamicin
 Consider acyclovir
 If 29-60 days old
Ceftriaxone ± Ampicillin OR Vancomycin
Until CSF results are known (cell count,
protein, glucose), initiate therapy with
meningitic dosing regimen
Treatment for febrile neutropenia
 Broad-spectrum antibiotics with Pseudomonas
coverage
 Ex: use ceftazidime or piperacillin-tazobactam
 Consider double coverage for possible resistant
Pseudomonas
 Ex: add amikacin or tobramycin
 Consider gram-positive coverage (central line,
skin infections)
 Ex: add vancomycin
 Consider anaerobic coverage (mucositis,
typhlitis)
 Ex: use piperacillin-tazobactam or add clindamycin
Take home points
 Infections are the most common cause of fever
in children
 During assessment of a child with fever, pay
close attention to vital sign changes, overall
appearance, and potential sites of infection
 Closely monitor for clinical decompensation after
antibiotic administration, particularly in patients
at high-risk of developing sepsis
References
 Baraff LJ. Management of fever without source in infants and
children. Ann Emerg Med. 2000. 36:602-14.
 Meckler G, Lindemulder S. Fever and neutropenia in pediatric
patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.
 Palazzi EL. Approach to the child with fever of unknown origin.
UpToDate. 2011
 Palazzi DL. Etiologies of fever of unknown origin. UpToDate.
2011.
 Tolan R. Fever of unknown origin: A diagnostic approach to this
vexing problem. Clin Pediatr. 2010;49:207-13.

More Related Content

Similar to fever-presentation.ppt

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinara
Kinara Kenyoru
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
tbf413
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patients
Ali Musavi
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TBAbhijeet Deshmukh
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022
vetindex4
 
Febrile neutropaenia
Febrile neutropaeniaFebrile neutropaenia
Febrile neutropaenia
Saqi Md. Abdul Baqi
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
Dr Shami Bhagat
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
intensivecaresociety
 
Septic shock in pediatric population 2021
Septic shock in pediatric population 2021Septic shock in pediatric population 2021
Septic shock in pediatric population 2021
Benson59
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
Nilesh Kucha
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Gamal Agmy
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaHarsha Vardhan
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAIJoseph Helms
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia
NITISH SHAH
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children
Pediatrics
 
HAP
HAPHAP
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
ShamiPokhrel2
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
ShamiPokhrel2
 

Similar to fever-presentation.ppt (20)

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinara
 
Fever infants
Fever infantsFever infants
Fever infants
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patients
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TB
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022
 
Febrile neutropaenia
Febrile neutropaeniaFebrile neutropaenia
Febrile neutropaenia
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
 
Septic shock in pediatric population 2021
Septic shock in pediatric population 2021Septic shock in pediatric population 2021
Septic shock in pediatric population 2021
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAI
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children
 
HAP
HAPHAP
HAP
 
Sepsis
SepsisSepsis
Sepsis
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 

More from Kiramat2

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptx
Kiramat2
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.ppt
Kiramat2
 
fever-presentation (1).ppt
fever-presentation (1).pptfever-presentation (1).ppt
fever-presentation (1).ppt
Kiramat2
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt
Kiramat2
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdf
Kiramat2
 
CMPA.pdf
CMPA.pdfCMPA.pdf
CMPA.pdf
Kiramat2
 

More from Kiramat2 (6)

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptx
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.ppt
 
fever-presentation (1).ppt
fever-presentation (1).pptfever-presentation (1).ppt
fever-presentation (1).ppt
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdf
 
CMPA.pdf
CMPA.pdfCMPA.pdf
CMPA.pdf
 

Recently uploaded

Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 

Recently uploaded (20)

Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 

fever-presentation.ppt

  • 1. Fever National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children’s Hospital
  • 2. Case 1  4-month-old well-appearing girl admitted for croup and respiratory distress. Develops fever to 39.1. What additional evaluation would you do at this point?
  • 3. Case 2  12-year old boy with AML, in induction, admitted for febrile neutropenia. He had just received his first dose of ceftazidime and vancomycin when he developed another fever to 38.5, chills, and new dizziness shortly after receiving the antibiotics. What would be the next steps in this patient’s management?
  • 4. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 5. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 6. Which patients are high-risk for sepsis?  Neonates  Transplant recipients Bone marrow Solid organ  Oncology patients Undergoing therapy, mucositis, central line Most chemotherapy: nadir ~ 10 days after rx  Asplenic patients, including sickle cell
  • 7. Definition of fever  38.0  Neonates (< 12 months)  Any immunocompromised patient  Including transplant patients, patients with immunodeficiencies, oncology patients (sustained ≥38 x 1 hour)  38.5  All other patients  These are general guidelines, individual patients/services may have different parameters
  • 8. What etiologies cause fever?  Infectious  Inflammatory  Oncologic  Other: CNS dysfunction, drug fever  Life-threatening conditions
  • 9. Infectious  Systemic  Bacteremia, sepsis, meningitis, endocarditis  Respiratory  URI, sinusitis, otitis media, pharyngitis, pneumonia, bronchiolitis  Abdominal  Urinary tract infection, abscess (liver, kidney, pelvis)  Bone/joint infection  Hardware infection  Central line, VP shunt, G-tube
  • 10. Inflammatory  Kawasaki disease  Juvenile inflammatory arthritis  Lupus  Inflammatory bowel disease  Henoch-Schonlein purpura
  • 12. Life-threatening conditions  Sepsis, febrile neutropenia  Vital sign instability, poor-perfusion, may have altered mental status, disseminated intravascular coagulation  Hemophagocytic lymphohistiocytosis  Splenomegaly, bicytopenia, elevated ferritin, elevated triglycerides, low fibrinogen, hemophagocytosis, low/absent NK cell function, elevated soluble IL2 receptor  Malignant hyperthermia  Following administration of inhaled anesthetics or depolarizing neuromuscular blockers (succinylcholine), at-risk patients include those with myopathy  Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
  • 13. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 14. Assessment  Vital signs  Repeat physical exam  Overall appearance (sick, toxic)  Central/peripheral lines  Incisions/wounds  VP shunt/tracheostomy/gastrostomy tube  Oral mucosa/perineal area for neutropenic patients  Perfusion  Call for help if concerning vital signs/exam  Fellow or attending  Rapid response team (RRT)/PICU
  • 15. Laboratory evaluation  What would you do if the patient has hardware (VP shunt, tracheostomy, gastrostomy tube) or central line? CBC with differential Blood culture CSF (tap VP shunt)
  • 16. Laboratory evaluation  What would you do if the patient has a high risk for sepsis? Immunocompromised Transplant recipient Oncology patient CBC with differential Blood culture Urinalysis and urine culture
  • 17. Laboratory evaluation  What would you do for an infant ≤ 2 months of age? CBC with differential Blood culture Catheterized urinalysis and urine culture Lumbar puncture
  • 18. Laboratory evaluation  Who needs a urinalysis and urine culture? Circumcised males < 6 months Uncircumcised males < 1 year Females < 2 years Immunocompromised patients Patients with history of UTI/pyelonephritis
  • 19. Laboratory evaluation  Who needs a lumbar puncture?  Neonates ≤ 2 months  Ill-appearing  Altered mental status  What tests do you send?  Gram stain and culture  Cell count and differential  Protein and glucose  Extra tube for additional studies  Enteroviral PCR, HSV PCR, CA encephalitis project
  • 20. Laboratory evaluation  Consider CRP, ESR  Consider PT/PTT, fibrinogen  Consider chest x-ray  Consider nasopharyngeal DFA  For immunosuppressed patients consider: Viral PCR studies (ie CMV, EBV, HHV6) Additional imaging (ie ultrasound, CT scan)
  • 21. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 22. Treatment for non-high risk patients  May not need empiric antibiotics  Consider the following issues: Is patient clinically stable? Are the screening laboratory studies suggestive of infection?
  • 23. Treatment for patients with central lines  Ceftriaxone  Vancomycin
  • 24. Treatment for neonates ≤ 2 months  If < 28 days old Ampicillin AND cefotaxime OR Ampicillin AND gentamicin  Consider acyclovir  If 29-60 days old Ceftriaxone ± Ampicillin OR Vancomycin Until CSF results are known (cell count, protein, glucose), initiate therapy with meningitic dosing regimen
  • 25. Treatment for febrile neutropenia  Broad-spectrum antibiotics with Pseudomonas coverage  Ex: use ceftazidime or piperacillin-tazobactam  Consider double coverage for possible resistant Pseudomonas  Ex: add amikacin or tobramycin  Consider gram-positive coverage (central line, skin infections)  Ex: add vancomycin  Consider anaerobic coverage (mucositis, typhlitis)  Ex: use piperacillin-tazobactam or add clindamycin
  • 26. Take home points  Infections are the most common cause of fever in children  During assessment of a child with fever, pay close attention to vital sign changes, overall appearance, and potential sites of infection  Closely monitor for clinical decompensation after antibiotic administration, particularly in patients at high-risk of developing sepsis
  • 27. References  Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000. 36:602-14.  Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.  Palazzi EL. Approach to the child with fever of unknown origin. UpToDate. 2011  Palazzi DL. Etiologies of fever of unknown origin. UpToDate. 2011.  Tolan R. Fever of unknown origin: A diagnostic approach to this vexing problem. Clin Pediatr. 2010;49:207-13.